COVID-19 vaccine ‘CanSino’ Appears Safe in the First Human Trial

Miss Chis

CanSino VACCINE – A coronavirus disease (COVID-19) vaccine was tested safe for humans for the first time and also it induces a rapid immune response, said the researchers at China’s CanSino Biologics Inc that is reported on Friday in The Lancet medical journal.

The blood samples from a group of 108 vaccinated adults showed both neutralizing antibodies and T-cell responses against the novel coronavirus in most of those tested.

However, further studies will be needed to confirm whether the vaccine protects against infection.

Based on the statement of co-author Professor Wei Chen from the Beijing Institute of Biotechnology in Beijing, he said;

These results represent an important milestone. The trial demonstrates that a single dose of the new adenovirus type 5 vectored COVID-19 (Ad5-nCoV) vaccine produces virus-specific antibodies and T cells in 14 days, making it a potential candidate for further investigation.

However … the ability to trigger these immune responses does not necessarily indicate that the vaccine will protect humans from COVID-19 … we are still a long way from this vaccine being available to all,” he added.

More than 100 vaccine candidates against SARS-CoV-2 are in development, with about 12 in human testing designed to mainly evaluate safety.

One of these including CanSino’s has moved to larger mid-stage studies that are evaluating the safety and the ability to induce an immune response.

Healthy adult volunteers in Wuhan, China, received a single intramuscular injection of either a low, middle or high dose of the vaccine.

Four weeks after the injection, the most common adverse reactions were mild pain at the injection site, fever, fatigue, headache, and muscle pain. There were no serious adverse events.

Meanwhile, the mid-stage trial of the vaccine is already underway in Wuhan.

What can you say about this? Share it below.

Leave a Comment